Atopic Dermatitis

Two important new therapies for atopic dermatitis were approved in 2017. With a robust pipeline following behind, researchers say more major advances could be on the horizon.

Based off positive phase 2b trial results, phase 3 will evaluate the safety and efficacy of PF-04965842.

The non-cancerous skin growths currently affect about 83 million US adults.

The study provides a blueprint for improving future bleach bath studies.

A new study helps better define when allergic sensitization and atopic dermatitis are predictive of asthma in infants.

The New Zealand-based over-the-counter therapy will be available for US patients on Amazon's website in 2018.

The drug's approval follows a unanimous positive opinion from the Vaccines and Related Biological Products advisory committee on Sept 13.

Dupixent, combined with topical corticosteroids significantly improved measures such as disease severity, skin clearing, itching, and overall quality of life in patients.

The study showed positive results for the drug and no new safety signals.

Already at war over PCSK9, drug giants go to court over another breakthrough drug.

Highly anticipated potential first-line treatment now a go in the United States.

"Not only has it shown efficacy in atopic dermatitis, but dupilumab also has shown efficacy in related atopic dermatitis conditions such as asthma and nasal polyps," said Akinlade.

Bola Akinlade, MD, MBA, Executive Director, Regeneron Pharmaceuticals, discussed the results of the dupilumab study presented at AAAAI 2017.

Luz Fonacier, MD, Winthrop University Hospital, detailed the process of looking at eczema and contact dermatitis in an allergist's practice.

The second of a two-part, year-end review of advances against eczema/dermatitis (AD) focused on treatment and prevention, noting there was little evidence showing "relative efficacy" of common systemic treatments.

An end-of-year two-part review highlighted that despite prevalent outcome measures, there is no consensus on the definition of a flare in atopic dermatitis.

Most dermatologists in the United Kingdom choose phototherapy first when treating adult patients with recalcitrant moderate-to-severe atopic eczema/dermatitis (AD).

The first study to associate genetic variances linked to skin barrier deficiencies and immune response in atopic eczema/dermatitis with the responses to treatment over several years has moved the field closer to individualizing precision therapies for the condition.

Skin conditions can cause physical, emotional, and financial duress. And, since atopic dermatitis in infants is often linked with asthma, allergies, hay fever, sleep problems, and weight issues, the total cost of eczema treatment could scale $3.8 billion annually.

An over-the-counter (OTC) treatment was considered superior to both the corticosteroid and an emollient cream in improving skin hydration.

Citing health hazards to patients and workers, the US Food and Drug Administration has issued a final rule banning the use of powdered exam gloves and surgical gloves. It will take effect January 19, 2017.

Not all herbal treatments were found to successfully treat moderate-to-severe eczema as previously thought.

A new drug for atopic dermatitis got FDA approval.

Previous research showed probiotics given to pregnant women during certain stages of pregnancy and post delivery reduced the likelihood of atopic dermatitis in their children. Recently published reports; however, may not agree.

Children with atopic dermatitis (AD) were reported to have a greater risk for developing contact dermatitis from some common ingredients of topical products than those with a history of contact dermatitis but no AD, in a recent comparison of patch testing responses in both groups.

Regeneron and Sanofi’s highly-anticipated atopic dermatitis drug dupilumab, trade name Dupixent, has been accepted by the European Medicines Agency (EMA) for review. The drug has performed well in trials and is considered an impending blockbuster.

Though air pollution has previously been associated with elevated rates of atopic dermatitis (AD), the reason for that correlation remained mostly a mystery until last week.

“While the concept of biofilms in atopic dermatitis is relatively new, antimicrobial and biofilm dispersing agents have been included in the treatment regimen for atopic dermatitis for decades," according to the study authors.

Multiple measurements of skin integrity and function were applied to distinguish between the effects of topical emollient products in a recent study. Two popular products in the UK were determined to transiently improve the skin barrier that is thought to be defective in atopic dermatitis (AD), and another product was confirmed to be damaging.

Researchers in Denmark recently reported that hospital-diagnosed atopic dermatitis is associated with a greater risk of myocardial infarction.